Global Headache Disorders Market Segments 2024, Forecast To 2033
5 Mar, 2024
The headache disorders market has experienced strong growth, increasing from $4.37 billion in 2023 to $4.7 billion in 2024, reflecting a 7.4% CAGR. Growth in the historic period is attributed to limited treatment options, growing awareness, rising incidence of headaches, evolving healthcare infrastructure, and a shift in lifestyle and stress levels. Looking ahead, the market is expected to see strong growth, reaching $6.42 billion in 2028 with an 8.1% CAGR. Drivers include digital health solutions, personalized medicine approaches, increasing research and development investments, global aging population, and the expansion of research in neuroinflammation.
Global Headache Disorders Market Key Driver
The headache disorders market is expected to expand due to the increasing prevalence of migraines. Migraines, characterized by severe throbbing pain, affect a significant global population. Reports from Migraine.com estimate around 39 million people in the United States and 1 billion worldwide experiencing migraines, contributing to the growing demand for headache disorders treatments.
Get A Free Sample Of The Global Headache Disorders Market ReportGlobal Headache Disorders Market Segments
The headache disorders market covered in this report is segmented –
1) By Type: Migraine, Tension-Type Headache, Cluster Headache, Medication-Overuse Headache, Other Types
2) By Treatment: Medication, Heat Therapy, Diet Changes, Acupuncture, Oxygen Therapy
3) By Diagnosis: Complete Blood Count, Skull X-Rays, Sinus X-Rays, CT Scan, Magnetic Resonance Imaging (MRI)
4) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
By Geography: The regions covered in the anti inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the headache disorders market in 2023. The regions covered in the headache disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Headache Disorders Industry Players
Teva Pharmaceutical Industries Ltd.; Hikma Pharmaceuticals PLC; Dr. Reddy's Laboratories Ltd; Novartis AG; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; Sun Pharmaceutical Industries Ltd; Emcure Pharmaceuticals Limited; Endo International plc; WorldMeds LLC; AstraZeneca plc; Bausch & Lomb Incorporated; Nichi-Iko Pharmaceutical Co; Upsher-Smith Laboratories LLC; Bristol-Myers Squibb Company; Bayer AG; Boehringer Ingelheim International GmbH.; Gilead Sciences Inc.; Amgen Inc.; Mylan N.V.; Pfizer Inc.; GlaxoSmithKline plc; Allergan plc; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Eisai Co. Ltd.; Impax Laboratories LLC; Lannett Company Inc.; Lupin Pharmaceuticals Inc.
Get The Full Global Headache Disorders Market Report
AIOps Headache Disorders Market Overview
Headache disorder is a neurological disorder that is characterized by severe headaches that reoccur on one side of the head, usually around the eye. Headache disorders create a major burden on sufferers, including significant personal pain, decreased quality of life, and financial consequences.
Headache Disorders Global Market Report 2023 provides data on the global headache disorders market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The headache disorders market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.